Postmenopausal hormone replacement therapy and cardiovascular system

被引:0
作者
Yildirir, Aylin [1 ]
机构
[1] Baskent Univ, Tip Fak, Kardiyol Anabilim Dali, Fevzi Cakmak Cad 10 Sok 45,C Blok 2 Kat,Bahceliev, TR-06490 Ankara, Turkey
来源
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY | 2010年 / 38卷
关键词
Menopause; hormone replacement therapy; cardiovascular risk;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Women suffer from cardiovascular diseases 10 years later than men, therefore female sex has been considered to be a 'protective factor'. However, the risk in women increases rapidly after menopause and the declining levels of endogenous estrogen is thought to be responsible. Postmenopausal hormone replacement therapy (HRT) decreases the severity and intensity of menopausal symptoms and improves women's quality of life. Until the last 10 years, based on the results of observational studies, postmenopausal HRT was thought to protect women against cardiovascular events and decrease the risk of coronary artery disease by 35-50%. However, recent randomized primary and secondary prevention trials did not support the cardioprotective effect of HRT. The different results of observational and randomized controlled trials are discussed to be related to the differences in the study population. The study population in observational and prospective cohort studies included relatively young women at the earlier stages of menopause, whereas studies showing neutral or negative effects of HRT included women older than 50 years old at least 10 years in menopause. Furthermore, the effects of estrogen depend on the state of vascular pathology. In relatively healthy vessels with no or early signs of atherosclerosis, estrogen prevent the development or progression of atherosclerotic lesions, whereas in the presence of established atherosclerotic lesions, estrogen promotes atherosclerosis or may even trigger acute events. Therefore, it is critically important to predict which women can safely receive HRT and which are at increased risk from HRT. Under the light of current knowledge, HRT should not be used for prevention from cardiovascular disease in postmenopausal women and the many other preventive strategies, (diet, exercise, blood pressure or cholesterol control) that are proven to be effective but underused, should be kept in mind.
引用
收藏
页码:32 / 40
页数:9
相关论文
共 42 条
  • [1] Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
    Adams, MR
    Register, TC
    Golden, DL
    Wagner, JD
    Williams, JK
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (01) : 217 - 221
  • [2] The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women
    Alexandersen, P
    Tankó, LB
    Bagger, YZ
    Qin, G
    Christiansen, C
    [J]. CLIMACTERIC, 2006, 9 (02) : 108 - 118
  • [3] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
    Anderson, GL
    Limacher, M
    Assaf, AR
    Bassford, T
    Beresford, SAA
    Black, H
    Bonds, D
    Brunner, R
    Brzyski, R
    Caan, B
    Chlebowski, R
    Curb, D
    Gass, M
    Hays, J
    Heiss, G
    Hendrix, S
    Howard, BV
    Hsia, J
    Hubbell, A
    Jackson, R
    Johnson, KC
    Judd, H
    Kotchen, JM
    Kuller, L
    LaCroix, AZ
    Lane, D
    Langer, RD
    Lasser, N
    Lewis, CE
    Manson, J
    Margolis, K
    Ockene, J
    O'Sullivan, MJ
    Phillips, L
    Prentice, RL
    Ritenbaugh, C
    Robbins, J
    Rossouw, JE
    Sarto, G
    Stefanick, ML
    Van Horn, L
    Wactawski-Wende, J
    Wallace, R
    Wassertheil-Smoller, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14): : 1701 - 1712
  • [4] Effect of oral postmenopausal hormone replacement on progression of atherosclerosis -: A randomized, controlled trial
    Angerer, P
    Störk, S
    Kothny, W
    Schmitt, P
    von Schacky, C
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (02) : 262 - 268
  • [5] Estrogen replacement reverses endothelial dysfunction in postmenopausal women
    Bush, DE
    Jones, CE
    Bass, KM
    Walters, GK
    Bruza, JM
    Ouyang, P
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 104 (06) : 552 - 558
  • [6] Cherry N, 2002, LANCET, V360, P2001
  • [7] Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x
  • [8] Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force
    Corretti, MC
    Anderson, TJ
    Benjamin, EJ
    Celermajer, D
    Charbonneau, F
    Creager, MA
    Deanfield, J
    Drexler, H
    Gerhard-Herman, M
    Herrington, D
    Vallance, P
    Vita, J
    Vogel, R
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) : 257 - 265
  • [9] Gast GC, 2008, HYPERTENSION, V51, P1
  • [10] Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women
    Gerhard, M
    Walsh, BW
    Tawakol, A
    Haley, EA
    Creager, SJ
    Seely, EW
    Ganz, P
    Creager, MA
    [J]. CIRCULATION, 1998, 98 (12) : 1158 - 1163